Etretinate is an aromatic retinoid that exhibits anti-inflammatory and anticancer activities. Etretinate was previously clinically used to treat psoriasis but has since been withdrawn due to high incidence of birth defects; it is currently considered teratogenic. This compound acts as an agonist at RARs and RXRs. Etretinate shows some potential in the treatment of cutaneous T-cell lymphoma.
| Cas No. | 54350-48-0 |
|---|---|
| Purity | ≥98% |
| Formula | C23H30O3 |
| Formula Wt. | 354.49 |
| Chemical Name | (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7- dimethyl-2,4,6,8-nonatetraenoic acid ethyl ester |
| IUPAC Name | ethyl(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate |
| Synonym | Tegison; Tigason |
| Melting Point | 104-105°C |
| Appearance | Yellow or Greenish-Yellow Crystalline Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | E7668 MSDS PDF |
|---|---|
| Info Sheet | E7668 Info Sheet PDF |
Burg G, Dummer R. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Clin Lymphoma. 2000 Nov;1 Suppl 1:S41-4. PMID: 11707863.
Saurat JH. Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol. 1999 Sep;41(3 Pt 2):S2-6. PMID: 10459139.
